Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Content Channel
Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF
If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.
Angus Liu
May 27, 2026 11:25am
AZ, Daiichi's Datroway approved in first-line TNBC
May 22, 2026 11:32am
Merck-Kelun, China deal wisdom, Takeda—Fierce Pharma Asia
May 22, 2026 8:53am
ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS
May 21, 2026 5:00pm
Enhertu secures dual FDA approvals in early breast cancer
May 18, 2026 10:52am
BMS-Hengrui, Takeda layoffs, Daiichi—Fierce Pharma Asia
May 15, 2026 8:30am
